News

A study in BMC Musculoskeletal Disorders suggests that multinucleated giant cells (MGC) may contribute to osteoarthritis (OA) and rheumatoid arthritis (RA) in addition to their known association with synovitis severity. The finding adds to other recent research and points to the therapeutic potential of targeting MGCs to improve pain and joint damage in both types of arthritis.

Gout has been making quite a stir in news recently. Between a new classification system and a study showing that a common food can cause painful flares, this form of arthritis is getting quite a bit of attention. Now comes word that a drug used to treat gout could also be effective for another damaging condition.

A systematic review of alopecia areata (AA) in Clinical, Cosmetic & Investigational Dermatology highlighted the unpredictability and lack of treatment options for the condition. But it also pointed to a larger problem: more than half of patients with AA experience poor health-related quality of life (QOL). Patients with AA are at risk for depression and anxiety, atopy, vitiligo, thyroid disease, and other autoimmune conditions.

A recent study in The Journal of Headache and Pain sheds some additional light on the chronobiological experience of patients with cluster headache (CH). However, it still leaves lingering mysteries around the pattern of pain CH that patients typically experience, the triggers of those headaches, and the mechanisms and interactions that drive headache frequency and severity.

B-cells that are active in lupus may also play a role in Sjögren’s syndrome. A new study finds that the same B-cell depleter drug, belimumab (Benlysta) approved for lupus, may also benefit Sjögren’s patients.

Social stressors, such as being treated poorly in a doctor’s office, can lead to negative disease outcomes, particularly among black women with lupus, a new study shows.

Complex regional pain syndrome (CRPS) is one of the pain conditions that has remained fairly mysterious, but a new, effective treatment may be on the horizon. It is known that CRPS most often develops following trauma, however, and evidence suggests a maladaptive response to nervous system damage involving immune and inflammatory pathways as well as abnormalities in both peripheral and central processing of afferent inputs. No single therapy – including pharmacologic therapy – wholly addresses the condition.

Patients with tophaceous gout rarely develop ulcers, but when they do occur, these ulcers can be difficult to treat. This case study explores the diagnosis of and treatment options for patients with ulcerated tophaceous gout.

Up to one-third of people with active ankylosing spondylitis (AS) have some degree of bone loss due to systemic inflammation and decreased mobility, but lowering inflammation with tumor necrosis factor blockers may improve bone density.